Clinical stage pharmaceutical development Company
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: BTHCF, Forum) announced on Tuesday that it has now enrolled 100 patients in its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19.
To learn more about this trial,
click here.
It was only a few weeks ago when AGN enrolled its
first 50 patients for this multinational human study of Ifenprodil for the treatment of the COVID-19 coronavirus.
Entitled,
“A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patients with Confirmed COVID-19 Disease,” this study gather a total of 150 patients who will either be treated using an existing standard of care, or standard of care plus Ifenprodil 60 mg, and doctors will see if there is an improvement in a number of secondary endpoints (mortality, blood oxygen levels, time in intensive care, time to mechanical ventilation).
FULL DISCLOSURE: Algernon Pharmaceuticals Inc. is a client of Stockhouse Publishing.